Genomic Classifier Predicts Prostate Cancer Therapy Benefit

A 22-gene test helps determine which prostate cancer patients benefit most from androgen deprivation therapy.

Updated on Oct. 15, 2026 in Cancer

Glass specimen slides on a backlit clinical table, representing genomic analysis. — Researchers identified that a 22-gene genomic classifier accurately predicts which prostate cancer patients benefit from androgen deprivation therapy. AI Illustration. Upload story photo >

Live Poll

Should genomic testing guide whether patients receive intensive cancer treatments?

Researchers presented findings on September 29, 2026, showing that a genomic classifier can identify patients likely to benefit from androgen deprivation therapy. The study demonstrates that high genomic risk scores are linked to a significant reduction in metastasis risk when using this treatment.

Why it matters

Distinguishing between patients who require treatment intensification and those who do not is essential for optimizing care. This tool helps clinicians avoid unnecessary treatments for patients unlikely to see significant benefits.

Analysis of 395 biopsy specimens showed 32% of patients had high genomic scores, which were associated with a 4.89 sub-hazard ratio for distant metastasis. Results follow a median study follow-up of 10.2 years.

The players

NRG/RTOG 0815 trial

This is a large-scale Phase 3 clinical study focused on improving treatment outcomes for prostate cancer patients.

NRG-GU010 trial

This is a future biomarker-driven Phase 3 clinical trial designed to validate the efficacy of genomic classifier testing.

The details

Investigators profiled archived biopsy specimens using a locked, clinical-grade Decipher 22-gene assay. The multivariable analysis accounted for age, race, clinical risk factors, comorbidity scores, and radiation therapy modality to ensure accuracy.

2026: NRG-GU010 phase 3 trial completed enrollment.
September 29, 2026: Study results presented at the ASTRO annual meeting.

The Big Picture

The study findings extend the clinical evidence base established by the NRG/RTOG 0815 trial.

This diagnostic tool could eventually help patients avoid unnecessary androgen deprivation therapy and its associated side effects. Patients should consult their oncologists regarding the availability of genomic classifier testing for their specific diagnosis.

The takeaway

Using genomic markers allows for a more personalized approach to prostate cancer treatment by identifying which patients truly need intensive therapy. This move toward precision medicine helps balance effective cancer control with the quality of life for the patient.

What happens next

The clinical utility of these genomic scores is scheduled for prospective validation through the phase 3 NRG-GU010 biomarker-driven trial, which completed enrollment in 2026.